You are here

Phase III Trial Evaluates Novel Insulin Inhalation Powder for Type 2 Diabetes

Study results due this summer (June 17)

Follow-up visits have been completed for patients enrolled in a phase III trial of Afrezza (MannKind Corporation), an investigational inhalation powder consisting of human insulin for the treatment of type 2 diabetes. The ultra rapid-acting mealtime insulin therapy is administered via an inhaler. Findings from the study are expected to be released later this summer.

The trial assessed Afrezza in patients with type 2 diabetes whose disease was inadequately controlled with metformin, with or without a second or third oral medication. After a run-in period, during which the patients remained on their oral medication, 353 patients were randomly assigned to receive additional treatment with Afrezza or a placebo inhalation powder. The study also included a titration period, followed by a 12-week evaluation period, to assess hemoglobin A1c levels.

Administered at the start of a meal, Afrezza dissolves immediately upon inhalation and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 14 minutes of administration, mimicking the release of meal-time insulin observed in healthy individuals. To date, the Afrezza clinical program has involved more than 5,600 adult patients.

Source: MannKind Corporation; June 17, 2013.

Recent Headlines

Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients